The Hepatitis B Foundation, Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center (PABC) today welcomed NIH Director Jay Bhattacharya, MD, PhD, for a visit highlighting collaborative research, innovation and academic programs advancing public health and biomedical discovery.U.S.

Kunwar Shailubhai PhD, MBA, a successful entrepreneur, accomplished scientist and inventor of the widely prescribed drug Trulance, has received the third annual Timothy M. Block, PhD, Biotech Impact Award from the Hepatitis B Foundation, Pennsylvania Biotechnology Center

The letter below will be sent to U.S. Congressman Guy Reschenthaler and Congresswoman Madeleine Dean on behalf of the Pennsylvania Ad Hoc NIH Funding Advocacy Coalition. A PDF version can be found here. To : Congressman Guy Reschenthaler

To celebrate the legacy of the late Nobel Laureate Baruch S. Blumberg, MD, DPhil, and to commemorate World Hepatitis Day, the Hepatitis B Foundation, Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center (PABC) held a sign unveiling

These innovators, experts and advocates are tackling the state's and the world's health challenges head on.The PABC's very own Bob Christmas, COO, is on the list.Read the full article on cityandstatepa.com.Against the headwinds of federal funding cuts, an

A team from the Pennsylvania Biotechnology Center (PABC) and B+Labs dove into BIO International, networking with industry leaders, government officials and other important participants at what organizers say is "the largest and most comprehensive event for biotechnology."The

Powered by the Hatch Biofund, the PABC’s 11th annual Entrepreneur Spotlight drew a capacity crowd. From among three stellar companies presenting at the Pennsylvania Biotechnology Center’s 11th annual Entrepreneur Spotlight pitch competition yesterday (June 5), a fast-growing

Louis P. Kassa III, MPA, chief executive officer of the Hepatitis B Foundation, Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center (PABC), was awarded an honorary Doctor of Humane Letters at Holy Family University’s recent 2025 Graduate Commencement

In today’s economic environment, even the most innovative life science companies are forced to make hard decisions, such as downsizing teams, consolidating operations or pausing ambitious growth plans. While these transitions are challenging, they also open the